EYPT - Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
2024-07-23 11:47:46 ET
Summary
- Today, we take a more in-depth look at small-cap biopharma Ocular Therapeutix, Inc.
- The company is focused on developing therapies for eye conditions using bioresorbable hydrogel-based technology.
- Ocular's lead clinical candidate, Axpaxli, is undergoing Phase 3 trials for wet AMD and NPDR, with potential peak sales forecasted at $600 million.
- Ocular has a potentially lucrative market it is targeting, but the stock is currently only appropriate for risk-tolerant investors.
- A full investment analysis around Ocular Therapeutix follows in the paragraphs below.
Shares of ophthalmology concern Ocular Therapeutix, Inc. ( OCUL ) have been on a rollercoaster ride recently. The shares rallied 200% trough-to-peak and subsequently cratering 64% in less than four months in 2024. Since then, they have again been on the rebound. Some optimism stemmed from the announcement of a $316.4 million private placement in February, while the selloff was fueled by tepid NPDR data from its lead clinical candidate Axpaxli. With results from a pivotal wet AMD trial due in 1Q25, one competitor removed from the NPDR indication, and cash to fund operations into 2028, Ocular merited a deeper dive. An analysis follows below....
Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors